Asset acquisitions - Ayala Pharmaceuticals - Narrative (Details) - Ayala Purchase Agreement $ / shares in Units, $ in Thousands	Mar. 25, 2024 USD ($) $ / shares shares
Asset acquisitions
Upfront consideration paid to Ayala	$ 20,039
Number of shares issued | shares	2,175,489
Common stock issued to Ayala	$ 50,645
Share price per share | $ / shares	$ 24.00
Percentage of discount related to unregistered share restrictions to be deducted from the share price	3.00%
Consideration paid	$ 71,341
Transaction costs	657
Maximum
Asset acquisitions
Amount required to be paid under the agreement	$ 37,500